KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Schrodinger (SDGR) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Schrodinger (SDGR) over the last 7 years, with Q3 2025 value amounting to $172.1 million.

  • Schrodinger's Cash & Equivalents rose 729.6% to $172.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $172.1 million, marking a year-over-year increase of 729.6%. This contributed to the annual value of $147.3 million for FY2024, which is 514.37% down from last year.
  • Schrodinger's Cash & Equivalents amounted to $172.1 million in Q3 2025, which was up 729.6% from $219.9 million recorded in Q2 2025.
  • Schrodinger's Cash & Equivalents' 5-year high stood at $568.2 million during Q1 2021, with a 5-year trough of $90.5 million in Q4 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $219.9 million (2025), whereas its average is $267.2 million.
  • In the last 5 years, Schrodinger's Cash & Equivalents skyrocketed by 26023.93% in 2021 and then plummeted by 7882.68% in 2022.
  • Schrodinger's Cash & Equivalents (Quarter) stood at $120.3 million in 2021, then dropped by 24.77% to $90.5 million in 2022, then skyrocketed by 71.67% to $155.3 million in 2023, then fell by 5.14% to $147.3 million in 2024, then increased by 16.83% to $172.1 million in 2025.
  • Its Cash & Equivalents was $172.1 million in Q3 2025, compared to $219.9 million in Q2 2025 and $326.0 million in Q1 2025.